J&J Stops Alzheimer's Study as Drug Proves Ineffective in Slowing Disease Progression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 25 2025
0mins
Should l Buy JNJ?
Source: Benzinga
Johnson & Johnson's Study Results: The Phase 2b AuTonomy study of posdinemab for early Alzheimer's disease did not achieve statistical significance in slowing clinical decline, leading to its discontinuation.
FDA Designation and Potential: Posdinemab received Fast Track designation from the FDA, showing potential to target phosphorylated tau in Alzheimer's patients, but its recent failure raises concerns for future Alzheimer's drug developments.
Novo Nordisk's Trial Findings: Novo Nordisk's phase 3 trials for semaglutide in early-stage Alzheimer's disease also failed to show superiority over placebo in reducing disease progression.
Market Reaction: Following the news, Johnson & Johnson's stock rose to a new 52-week high, trading at $206.99, reflecting investor sentiment despite the study setback.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 230.690
Low
190.00
Averages
218.50
High
240.00
Current: 230.690
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Signs Order to Accelerate Psychedelic Drug Research
- Policy Driving Research: President Trump signed an executive order directing health regulators to expedite reviews of psychedelic drugs and increase federal funding, responding to advocates like Joe Rogan, indicating a governmental acknowledgment of the potential medical uses of psychedelics.
- Clinical Trial Progress: Current trials show strong evidence for the use of psychedelics in treating severe depression and PTSD, particularly in patients unresponsive to existing treatments, suggesting these drugs could become viable new therapeutic options.
- Drug Authorization Status: In the U.S., Johnson & Johnson's esketamine nasal spray is approved for treatment-resistant depression, while countries like Australia and Switzerland have authorized psilocybin and MDMA for various uses, reflecting a global recognition of the therapeutic potential of psychedelics.
- Risk Assessment: Despite the therapeutic promise of psychedelics, risks such as acute anxiety and confusion during administration, as well as higher risks when used outside clinical settings, highlight the need for caution in their research and application.
See More
Apple's New CEO Takes Over Amid Optimistic Market Outlook
- Apple Leadership Change: Apple announced that Senior Vice President of Hardware Engineering John Ternus will take over as CEO on September 1, succeeding Tim Cook, who has led the company to a market cap increase of over 20 times to $4 trillion since 2011, presenting Ternus with significant leadership challenges.
- UnitedHealth Earnings Beat: UnitedHealth reported strong quarterly results with a medical benefit ratio of 83.9%, better than the 85.5% consensus, leading to a more than 7% increase in shares, alongside a plan to buy back at least $2 billion in stock by Q2, indicating robust financial health.
- GE Aerospace Performance: GE Aerospace's quarterly results exceeded expectations with orders rising 87% to $23 billion and revenue increasing 25% to $12.39 billion, and despite travel issues in Asia and the U.S., management maintained prior guidance, reflecting ongoing improvements in the defense sector.
- Amazon's Increased Investment: Amazon is boosting its investment in AI company Anthropic by an additional $5 billion, with an option for $20 billion more upon achieving commercial milestones, aiming to reduce reliance on Nvidia and address the growing demand for computing power, showcasing Amazon's strategic positioning in the AI landscape.
See More
Dagco Increases Sellas Stake to 1.01% Ahead of Key Data
- Stake Increase: Dagco added 451,240 shares of Sellas Life Sciences on Tuesday, bringing its total holdings to 1.03 million shares valued at $4.35 million, making it the second-largest holding at 1.01% of its portfolio, indicating strong confidence in Sellas' future prospects.
- Clinical Data Catalyst: Sellas is set to present preclinical data on SLS009 at the AACR conference, targeting acute myeloid leukemia (AML), with lab studies showing that it induces leukemia cell death by enhancing caspase-3 activity, potentially offering new treatment options for AML patients.
- Regal Trial Progress: The Phase 3 Regal trial has recorded 72 survival events, moving closer to the 80-event threshold for final analysis, with the CEO suggesting that the slower accumulation of events may indicate longer patient survival, further heightening investor expectations.
- Optimistic Market Sentiment: Retail sentiment for SLS on Stocktwits is deemed 'extremely bullish' amid high message volume, with investors generally optimistic about the potential of SLS009, reflecting positive market expectations for Sellas' future developments.
See More
Investors Should Beware of Chasing Hot Stocks
- Market Warning: CNBC's Jim Cramer cautions that investors chasing 'parabolic' moves often face significant losses, advocating instead for overlooked stocks as better investment opportunities.
- Healthcare Stock Investment: Despite the healthcare sector being the worst performer in the S&P 500, Cramer purchased shares of Johnson & Johnson through his Charitable Trust, emphasizing that buying quality companies during price declines is a rare opportunity.
- Fundamental Analysis: Cramer believes that recent weakness in J&J's stock is largely driven by 'noise' related to talc lawsuits, overshadowing significant developments like new drug approvals and strategic business changes, highlighting short-sighted market sentiment.
- Portfolio Strategy: Cramer stresses the importance of maintaining a balance between hot and cold stocks in an investment portfolio to mitigate the risk of market leaders quickly losing favor, advising against an over-concentration in technology stocks to avoid losses.
See More
Johnson & Johnson Shares Enter Oversold Territory
- Oversold Signal: Johnson & Johnson (JNJ) shares entered oversold territory on Monday with an RSI of 29.5, indicating that the recent heavy selling pressure may be exhausting, prompting investors to seek buying opportunities.
- Price Fluctuation: JNJ's stock price dipped to a low of $229.62, with the last trade at $230.69, showing significant volatility compared to its 52-week low of $146.115 and high of $251.71, reflecting varying market expectations for its future performance.
- Market Comparison: In contrast to the S&P 500 ETF (SPY) with an RSI of 69.1, JNJ's low RSI may attract investors looking for rebound opportunities, highlighting a divergence in market sentiment.
- Investor Strategy: Given the oversold signal, investors may reassess JNJ's value and consider accumulating shares during price corrections, aiming to profit from potential market rebounds in the future.
See More
Eli Lilly to Acquire Kelonia Therapeutics for Up to $7 Billion
- Acquisition Agreement Details: Eli Lilly has entered into a definitive agreement to acquire Kelonia Therapeutics for up to $7 billion, with $3.25 billion payable upfront and the remainder contingent on clinical, regulatory, and commercial milestones, indicating Lilly's strategic intent to expand in oncology.
- Optimistic Clinical Outlook: Kelonia's lead program, KLN-1010, is a Phase 1 investigational therapy for relapsed and refractory multiple myeloma that utilizes an in vivo gene delivery system to generate CAR-T cells directly in patients, potentially offering new hope by simplifying existing treatment complexities.
- Competitive Market Pressure: This acquisition positions Lilly in a market with established competitors, as Johnson & Johnson's CAR-T treatment Carvykti generated $1.89 billion in sales last year, while Gilead recently paid $7.8 billion for Arcellx and its rival drug, highlighting the intense competition in the sector.
- Strategic Significance: Lilly's executive Jacob Van Naarden noted that early clinical data is highly encouraging, representing not only a potential advancement for multiple myeloma patients but also validating Kelonia's platform concept, showcasing Lilly's ongoing investment and innovation capabilities in biopharmaceuticals.
See More
Trump Signs Order to Accelerate Psychedelic Drug Research
- Policy Driving Research: President Trump signed an executive order directing health regulators to expedite reviews of psychedelic drugs and increase federal funding, responding to advocates like Joe Rogan, indicating a governmental acknowledgment of the potential medical uses of psychedelics.
- Clinical Trial Progress: Current trials show strong evidence for the use of psychedelics in treating severe depression and PTSD, particularly in patients unresponsive to existing treatments, suggesting these drugs could become viable new therapeutic options.
- Drug Authorization Status: In the U.S., Johnson & Johnson's esketamine nasal spray is approved for treatment-resistant depression, while countries like Australia and Switzerland have authorized psilocybin and MDMA for various uses, reflecting a global recognition of the therapeutic potential of psychedelics.
- Risk Assessment: Despite the therapeutic promise of psychedelics, risks such as acute anxiety and confusion during administration, as well as higher risks when used outside clinical settings, highlight the need for caution in their research and application.
See More
Apple's New CEO Takes Over Amid Optimistic Market Outlook
- Apple Leadership Change: Apple announced that Senior Vice President of Hardware Engineering John Ternus will take over as CEO on September 1, succeeding Tim Cook, who has led the company to a market cap increase of over 20 times to $4 trillion since 2011, presenting Ternus with significant leadership challenges.
- UnitedHealth Earnings Beat: UnitedHealth reported strong quarterly results with a medical benefit ratio of 83.9%, better than the 85.5% consensus, leading to a more than 7% increase in shares, alongside a plan to buy back at least $2 billion in stock by Q2, indicating robust financial health.
- GE Aerospace Performance: GE Aerospace's quarterly results exceeded expectations with orders rising 87% to $23 billion and revenue increasing 25% to $12.39 billion, and despite travel issues in Asia and the U.S., management maintained prior guidance, reflecting ongoing improvements in the defense sector.
- Amazon's Increased Investment: Amazon is boosting its investment in AI company Anthropic by an additional $5 billion, with an option for $20 billion more upon achieving commercial milestones, aiming to reduce reliance on Nvidia and address the growing demand for computing power, showcasing Amazon's strategic positioning in the AI landscape.
See More
Dagco Increases Sellas Stake to 1.01% Ahead of Key Data
- Stake Increase: Dagco added 451,240 shares of Sellas Life Sciences on Tuesday, bringing its total holdings to 1.03 million shares valued at $4.35 million, making it the second-largest holding at 1.01% of its portfolio, indicating strong confidence in Sellas' future prospects.
- Clinical Data Catalyst: Sellas is set to present preclinical data on SLS009 at the AACR conference, targeting acute myeloid leukemia (AML), with lab studies showing that it induces leukemia cell death by enhancing caspase-3 activity, potentially offering new treatment options for AML patients.
- Regal Trial Progress: The Phase 3 Regal trial has recorded 72 survival events, moving closer to the 80-event threshold for final analysis, with the CEO suggesting that the slower accumulation of events may indicate longer patient survival, further heightening investor expectations.
- Optimistic Market Sentiment: Retail sentiment for SLS on Stocktwits is deemed 'extremely bullish' amid high message volume, with investors generally optimistic about the potential of SLS009, reflecting positive market expectations for Sellas' future developments.
See More
Investors Should Beware of Chasing Hot Stocks
- Market Warning: CNBC's Jim Cramer cautions that investors chasing 'parabolic' moves often face significant losses, advocating instead for overlooked stocks as better investment opportunities.
- Healthcare Stock Investment: Despite the healthcare sector being the worst performer in the S&P 500, Cramer purchased shares of Johnson & Johnson through his Charitable Trust, emphasizing that buying quality companies during price declines is a rare opportunity.
- Fundamental Analysis: Cramer believes that recent weakness in J&J's stock is largely driven by 'noise' related to talc lawsuits, overshadowing significant developments like new drug approvals and strategic business changes, highlighting short-sighted market sentiment.
- Portfolio Strategy: Cramer stresses the importance of maintaining a balance between hot and cold stocks in an investment portfolio to mitigate the risk of market leaders quickly losing favor, advising against an over-concentration in technology stocks to avoid losses.
See More
Johnson & Johnson Shares Enter Oversold Territory
- Oversold Signal: Johnson & Johnson (JNJ) shares entered oversold territory on Monday with an RSI of 29.5, indicating that the recent heavy selling pressure may be exhausting, prompting investors to seek buying opportunities.
- Price Fluctuation: JNJ's stock price dipped to a low of $229.62, with the last trade at $230.69, showing significant volatility compared to its 52-week low of $146.115 and high of $251.71, reflecting varying market expectations for its future performance.
- Market Comparison: In contrast to the S&P 500 ETF (SPY) with an RSI of 69.1, JNJ's low RSI may attract investors looking for rebound opportunities, highlighting a divergence in market sentiment.
- Investor Strategy: Given the oversold signal, investors may reassess JNJ's value and consider accumulating shares during price corrections, aiming to profit from potential market rebounds in the future.
See More
Eli Lilly to Acquire Kelonia Therapeutics for Up to $7 Billion
- Acquisition Agreement Details: Eli Lilly has entered into a definitive agreement to acquire Kelonia Therapeutics for up to $7 billion, with $3.25 billion payable upfront and the remainder contingent on clinical, regulatory, and commercial milestones, indicating Lilly's strategic intent to expand in oncology.
- Optimistic Clinical Outlook: Kelonia's lead program, KLN-1010, is a Phase 1 investigational therapy for relapsed and refractory multiple myeloma that utilizes an in vivo gene delivery system to generate CAR-T cells directly in patients, potentially offering new hope by simplifying existing treatment complexities.
- Competitive Market Pressure: This acquisition positions Lilly in a market with established competitors, as Johnson & Johnson's CAR-T treatment Carvykti generated $1.89 billion in sales last year, while Gilead recently paid $7.8 billion for Arcellx and its rival drug, highlighting the intense competition in the sector.
- Strategic Significance: Lilly's executive Jacob Van Naarden noted that early clinical data is highly encouraging, representing not only a potential advancement for multiple myeloma patients but also validating Kelonia's platform concept, showcasing Lilly's ongoing investment and innovation capabilities in biopharmaceuticals.
See More
